Skip to main content

Table 3 Multivariate analysis for overall survival

From: Outcome of therapy-related myeloid neoplasms treated with azacitidine

  Hazard Ratio p 95% C.I.
WHO type (t-AML vs t-MDS) 3.49 0.03 1.17-10.46
Karyotype (aberrant versus normal) 2.2 0.015 0.75-6.58
Front-line AZA (no vs yes) 3.45 0.08 0.87-13.62